The worldwide antifungal medications market was worth USD 13.81 billion in 2021 and is predicted to grow at a 3.6% CAGR over the forecast period. Increasing high-value investments in the healthcare sector, as well as R&D endeavors by big...
Derren Healthcare Private Limited (DHPL) and Genpharmasec Limited (SSSA) have signed a share purchase and share subscription cum shareholders' agreement (SSSA). Following that, Genpharmasec will gradually acquire a 70% share in DHPL over the...
Indian-origin computational Neuroscientist Dr Srikanth Ramaswamy has been announced as one of six new Fellows for the 2023 Lister prize for his early-career success that indicated an exceptional potential for future biomedical research. His work...
EffRx Pharmaceuticals SA, a commercial-stage pharmaceutical company focused on the development and commercialization of medications for musculoskeletal and rare diseases, announced that it has signed an exclusive licensing and distribution...
CureVac, in collaboration with GSK, recently announced the entry of its modified mRNA seasonal influenza vaccine candidate with multiple antigens into Phase II clinical trials. The preliminary results of Phase I trials demonstrated favorable...
BioNTech of Germany has announced a collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to further the development of its mpox vaccine. CEPI will provide funding of up to $90 million to support the development of vaccine...
Torrent Pharmaceuticals is in talks with private equity firms CVC Capital Partners and Bain Capital to raise cash for a stake in Cipla. The Indian pharmaceutical company intends to fund up to $1.5 billion in order to bid for Cipla...
The National Institutes of Health (NIH) in the United States announced the start of an early-stage research on an experimental vaccine targeting six strains of influenza virus. The vaccine candidate, FluMos-v2, is intended to protect against four...
vThe United States Food and Drug Administration (USFDA) has granted final approval to Zydus Lifesciences for Norelgestromin and Ethinyl Estradiol Transdermal System, 150 mcg/35 mcg per day (USRLD: Ortho Evra Transdermal System, 150 mcg/35 mcg per...
One of the most promising developments in the constantly developing field of medicine is pharmacologists.
.jpg)
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")